RxDoctor Payments Data

Maria Mas, MD

Internal Medicine · Coral Gables, FLNPI 1679558084

Payments from drug & device makers

$4,314in general payments, 2019–2025

Across 125 payments — averaging $34.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$3K
  • Novartis$249
  • Lilly USA, LLC$137
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$132
  • Boehringer Ingelheim$121
  • Actelion Pharmaceuticals US, Inc.$114
  • plus $977 from 19 others

What the payments were for

  • Food & beverage$4,21998%
  • Education$952%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,314 in reported general payments places this provider in the 85th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$22,663
Medicare patients
68
Services billed
192

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban79$47,622
TradjentaLinagliptin49$45,319
OzempicSemaglutide35$40,462
EliquisApixaban30$32,138
EntrestoSacubitril/Valsartan34$30,652
Repatha SureclickEvolocumab44$30,631
JardianceEmpagliflozin22$19,723
LinzessLinaclotide11$14,706
MultaqDronedarone Hcl11$6,011
Stiolto RespimatTiotropium Br/Olodaterol Hcl14$5,000
SynthroidLevothyroxine Sodium46$4,450
Chlordiazepoxide-ClidiniumChlordiazepoxide/Clidinium Br14$4,169
Climara ProEstradiol/Levonorgestrel13$3,243
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate16$2,693
Clorazepate Dipotassium27$1,874

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimTradjenta, Jardiance, Stiolto Respimat$121$70,04285 claims
Johnson & JohnsonXarelto$62$47,62279 claims
Novo NordiskOzempic$57$40,46235 claims
PfizerEliquis$86$32,13830 claims
NovartisEntresto$249$30,65234 claims
AbbVieLinzess, Synthroid$78$19,15657 claims
BayerClimara Pro$23$3,24313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Coral Gables

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →